Please Welcome Our New Board Officers

ASGCT Staff - May 04, 2020

We'd like to congratulate and welcome these five new officers to the ASGCT Board of Directors!

The Board and the Society's officers are responsible for the management, direction, and control of the business, policies, and affairs of ASGCT. All of the new Board members will serve three-year terms, and the incoming Vice President will ascend through the presidential succession process before serving as ASGCT President in 2022-23.

Vice President

Hans-Peter Kiem, M.D., Ph.D.
Fred Hutchinson Cancer Research Center

Dr. Kiem is a physician-scientist studying hematopoietic stem cell (HSC) biology, transplantation, immunotherapy and gene therapy/genome editing. He's also a trained and clinically active oncologist seeing patients on the marrow transplant and immunotherapy services.


Paloma Giangrande, Ph.D.
Moderna Therapeutics

Dr. Giangrande's career has been dedicated to the investigation and development of RNA-based therapeutic approaches (including RNA aptamers, siRNAs, and mRNA) for cancer, cardiovascular disease, rare diseases, and critical illness.

At-Large Director

Marcela Maus, M.D., Ph.D.
Harvard University

Dr. Maus has extensive experience in the biology of T-cell activation and clinical translation of gene-modified T cells. She has 20+ years of basic laboratory research experience in T-cell biology, as well as unique expertise in bringing novel cell and gene therapies from the laboratory to the clinic.

At-Large Director

Federico Mingozzi, Ph.D.
Spark Therapeutics

Dr. Mingozzi's career has focused on the development of safe and effective gene-based treatments for genetic and acquired diseases. Large parts of his work have been centered on understanding the interactions between gene therapy vectors and host immune systems.

At-Large Director, Scientific & Research Council Chair

Anastasia Khvorova, Ph.D.
University of Massachusetts Medical School

For 20 years, Dr. Khvorova has focused her research efforts on RNA chemical biology and oligonucleotide technology development. Her diverse expertise in chemistry and cell biology allowed her to establish a lab that brings together hard-core organic chemists and RNA biologists to develop novel approaches and solutions to understanding natural and therapeutic RNA trafficking and delivery.

Related Articles


ASGCT Statement of Support for the Asian, Asian-American and Pacific Islander Communities

ASGCT Board of Directors - April 27, 2021

Gene, Cell, & RNA Therapy Landscape: Q1 2021

David M. Barrett, J.D., M.S. - April 15, 2021

New Diversity and Inclusion Awards Aim to Promote Equity in Gene and Cell Therapy Research

David Barrett, J.D., M.S. - February 26, 2021

Second mRNA Vaccine for COVID-19 Approved in the U.S.

Stephen J. Russell, M.D., Ph.D. - December 18, 2020